Press Releases

    • January 3, 2024

    Important Update on Listing Status and Strategic Direction

    Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) — Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a...

    Read more
    December 13, 2023

    Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

    Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer...

    Read more
    November 14, 2023

    Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

    Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough,...

    Read more
    November 13, 2023

    Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

    Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    September 14, 2023

    Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

    LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    September 14, 2023

    Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

    LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    September 12, 2023

    Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

    LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    September 11, 2023

    Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

    LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    August 17, 2023

    Nemaura Medical Announces SFDA Approval of sugarBEAT®

    Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    August 14, 2023

    Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update

    Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more